Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
Timothy Devos, Quentin Van Thillo, Veerle Compernolle, et al.
European Respiratory Journal (2021) Vol. 59, Iss. 2, pp. 2101724-2101724
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 129
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 107
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 91
Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients
Benoît Misset, Michaël Piagnerelli, Eric A. J. Hoste, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 17, pp. 1590-1600
Open Access | Times Cited: 53
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma
Lise J Estcourt, Claudia S. Cohn, Monica B. Pagano, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 9, pp. 1310-1321
Open Access | Times Cited: 66
Convalescent plasma for people with COVID-19: a living systematic review
Claire Iannizzi, Khai Li Chai, Vanessa Piechotta, et al.
Cochrane library (2023) Vol. 2024, Iss. 2
Closed Access | Times Cited: 34
Convalescent plasma for people with COVID-19: a living systematic review
Claire Iannizzi, Khai Li Chai, Vanessa Piechotta, et al.
Cochrane library (2023) Vol. 2023, Iss. 2
Open Access | Times Cited: 31
Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis
Jonathon W. Senefeld, Ellen K. Gorman, Patrick W. Johnson, et al.
Mayo Clinic Proceedings Innovations Quality & Outcomes (2023) Vol. 7, Iss. 5, pp. 499-513
Open Access | Times Cited: 30
A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19
Yogiraj Ray, Shekhar Ranjan Paul, Purbita Bandopadhyay, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 37
IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers
Bram Decru, Jan Van Elslande, Sophie Steels, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials
Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Kalliopi Sekeri, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 765-765
Open Access | Times Cited: 17
Convalescent plasma and predictors of mortality among hospitalized patients with COVID-19: a systematic review and meta-analysis
Massimo Franchini, Mario Cruciani, Carlo Mengoli, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1514-1522
Closed Access | Times Cited: 8
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Jiawen Deng, Kiyan Heybati, Harikrishnaa Ba Ramaraju, et al.
Infection (2022) Vol. 51, Iss. 1, pp. 21-35
Open Access | Times Cited: 26
Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial
Els Tobback, Sophie Degroote, Sabine Buysse, et al.
International Journal of Infectious Diseases (2022) Vol. 122, pp. 628-635
Open Access | Times Cited: 24
The structure of lipopeptides impacts their antiviral activity and mode of action against SARS-CoV-2 in vitro
Alexis C. R. Hoste, Willy Smeralda, Aurélien Cugnet, et al.
Applied and Environmental Microbiology (2024) Vol. 90, Iss. 11
Open Access | Times Cited: 5
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
Sixten Körper, Beate Grüner, Daniel Zickler, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 24
Open Access | Times Cited: 21
Early administration of COVID‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
Artur Belov, Yin Huang, Carlos H. Villa, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 6, pp. 770-779
Open Access | Times Cited: 15
Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis
Jonathon W. Senefeld, Ellen K. Gorman, Patrick W. Johnson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
Unlocking the therapeutic potential of edible mushrooms: Ganoderma and their secondary metabolites as novel antiviral agents for combating COVID-19
Samantha C. Karunarathna, Wenhua Lu, Nimesha Patabedige, et al.
New Zealand Journal of Botany (2024), pp. 1-59
Closed Access | Times Cited: 2
Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters
Elise Wouters, Caro Verbrugghe, Rana Abdelnabi, et al.
EBioMedicine (2023) Vol. 92, pp. 104597-104597
Open Access | Times Cited: 5
Immune Plasma for the Treatment of COVID-19: Lessons Learned so far
Hubert Schrezenmeier, Simone Hoffmann, Henrike Hofmann, et al.
Hämostaseologie (2023) Vol. 43, Iss. 01, pp. 067-074
Open Access | Times Cited: 5
The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials
Zhenbei Qian, Zhijin Zhang, Haomiao Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials
Denise Battaglini, Chiara Robba, Paolo Pelosi, et al.
Expert Opinion on Emerging Drugs (2022) Vol. 27, Iss. 2, pp. 187-209
Closed Access | Times Cited: 7
Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study
Fabrice Cognasse, Hind Hamzeh‐Cognasse, Mickaël Rosa, et al.
EBioMedicine (2022) Vol. 87, pp. 104414-104414
Open Access | Times Cited: 7
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial
Maxime Desmarets, Simone Hoffmann, Charline Vauchy, et al.
BMJ Open (2023) Vol. 13, Iss. 4, pp. e071277-e071277
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top